F. Gonçalves

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

J. Kliment, C. Robertson, P. Whelan, 2008 .

Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer

G. Kramer, R. Cathomas, D. Pacík, 2014, Urologia Internationalis.

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.

J. Kliment, T. Oliver, C. Robertson, 2014, European urology.

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.

V. Khoo, Z. Filipovic, N. Vogelzang, 2022, JAMA oncology.

Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control

S. Ziaran, J. Breza, F. Gonçalves, 2013, World Journal of Urology.

Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy.

S. Ziaran, F. Gonçalves, J. B. Sn, 2013, Clinical genitourinary cancer.